Our results showing frequent loss of p16 expression in the entire tumor or focally (7/9 H3 K27M and 6/8 wt cases) have implications that should be considered more largely, as they may open the path for therapies targeting the p16 pathway (e.g., CDK4 or cyclin D1) in this population. This evidence concerns the gene CDK4 and neoplasm.